Loading clinical trials...
Loading clinical trials...
Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis
Conditions
Interventions
SYM-1219
Locations
40
United States
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Jonesboro, Arkansas, United States
La Mesa, California, United States
San Diego, California, United States
Colorado Springs, Colorado, United States
Start Date
June 1, 2015
Primary Completion Date
October 1, 2015
Completion Date
October 1, 2015
Last Updated
April 13, 2021
NCT07394777
NCT01829204
NCT04046900
NCT04771728
NCT06472765
NCT05666778
Lead Sponsor
Symbiomix Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions